Patients with ALK-positive, advanced non–small cell lung cancer who received crizotinib beyond progressive disease demonstrated longer OS than patients who did not continue treatment, according to results of a retrospective study.
The analysis included 194 patients treated with crizotinib (Xalkori, Pfizer) who experienced progressive disease defined by RECIST criteria. Of them, 120 (62%) demonstrated ongoing clinical benefit and continued treatment with crizotinib for more than 3 weeks.
Sai-Hong I. Ou
Patients with progressive disease as best response to initial crizotinib were excluded from the analysis.
More patients who continued treatment with crizotinib had an ECOG performance status of 0 or 1 at the time of disease progression (96% vs. 82%; P=.02).
Overall, crizotinib continuation was associated with significantly prolonged median OS from the time of progressive disease (16.4 months vs. 3.9 months; HR=0.27; 95% CI, 0.17-0.42) and from the time of crizotinib initiation (29.6 months vs. 10.8 months; HR=0.3; 95% CI, 0.19-0.46) compared with treatment discontinuation.
Crizotinib continuation remained significantly associated with longer OS after adjustments for relevant factors, researchers wrote.
“Crizotinib is approved to treat advanced ALK-positive NSCLC, but most patients ultimately develop progressive disease,” the researchers wrote. “Continuing ALK inhibition with crizotinib after progressive disease may provide survival benefit to patients with advanced ALK-positive NSCLC.”
Disclosure: See the study for a full list of the researchers’ relevant financial disclosures.